Product Description
MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02500680)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nova Biomedical
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Influenza, Human
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02500680 |
MER4101 | P1 |
Unknown status |
Influenza, Human |
2020-12-01 |
50% |
2021-09-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|